Editing Clarithromycin (section)

==Medical uses==
===Antibiotic===
Clarithromycin is primarily used to treat a number of bacterial infections including [[pneumonia]], ''[[Helicobacter pylori]]'', and as an alternative to [[penicillin]] in [[strep throat]].<ref name=AHFS2015/> Other uses include [[cat scratch disease]] and other infections due to [[Bartonella]], [[cryptosporidiosis]], as a second line agent in [[Lyme disease]] and [[toxoplasmosis]].<ref name=AHFS2015/> It may also be used to prevent [[bacterial endocarditis]] in those who cannot take penicillin.<ref name=AHFS2015/> It is effective against upper and lower respiratory tract infections, skin and soft tissue infections and [[helicobacter pylori]] infections associated with duodenal ulcers.{{cn|date=March 2023}}

==== Spectrum of bacterial susceptibility ====
{{More citations needed|section|date=February 2018}}
Aerobic Gram-positive bacteria
* ''[[Staphylococcus aureus]]''
* ''[[Streptococcus pneumoniae]]''
* ''[[Streptococcus pyogenes]]''
Aerobic Gram-negative bacteria
* Haemophilus parainfluenzae&nbsp;
* ''[[Haemophilus influenzae]]''
* ''[[Moraxella catarrhalis]]''
Helicobacter
* [[Helicobacter pylori]]
Mycobacteria

[[Mycobacterium avium complex]] consisting of:
* [[Mycobacterium avium avium]]
* [[Mycobacterium intracellulare]]
Other bacteria
* ''[[Chlamydia pneumoniae]]''
* ''[[Mycoplasma pneumoniae]]''

Safety and effectiveness of clarithromycin in treating clinical infections due to the following bacteria have not been established in adequate and well-controlled clinical trials:<ref name="biaxin-filmtab" />

Aerobic Gram-positive bacteria
* [[Streptococcus agalactiae]]
* [[Streptococcus|Streptococcus (Groups C, F, G)]]
* Viridans group streptococci
Aerobic Gram-negative bacteria
* [[Bordetella pertussis]]
* [[Legionella pneumophila]]
* [[Pasteurella multocida]]
Anaerobic Gram-positive bacteria
* [[Clostridium perfringens]]
* Peptococcus niger
* [[Cutibacterium acnes]]
Anaerobic Gram-negative bacteria
* Prevotella melaninogenica (formerly [[Bacteroides melaninogenicus]])

=== Idiopathic hypersomnia ===
Clarithromycin has been researched as a potential treatment for [[idiopathic hypersomnia]] (IH) in adults, but the evidence is limited. A 2021 [[Cochrane (organisation)|Cochrane]] study determined that the evidence is inadequate to definitively determine the efficacy of clarithromycin in the management of idiopathic hypersomnia.<ref name="pmid34031871">{{cite journal |vauthors=Trotti LM, Becker LA, Friederich Murray C, Hoque R |title=Medications for daytime sleepiness in individuals with idiopathic hypersomnia |journal=The Cochrane Database of Systematic Reviews |volume=2021 |issue=5 |pages=CD012714 |date=May 2021 |pmid=34031871 |pmc=8144933 |doi=10.1002/14651858.CD012714.pub2 |quote=There is insufficient evidence to conclude whether clarithromycin is effective for the treatment of idiopathic hypersomnia.}}</ref> The [[American Academy of Sleep Medicine|American Academy of Sleep Medicine's]] 2021 clinical practice guidelines conditionally suggested its use, especially for those who don't respond to other therapies.<ref name="pmid34743789">{{cite journal |vauthors=Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, Watson NF |title=Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline |journal=Journal of Clinical Sleep Medicine |volume=17 |issue=9 |pages=1881–1893 |date=September 2021 |pmid=34743789 |pmc=8636351 |doi=10.5664/jcsm.9328 |quote=Recommendation 9: We suggest that clinicians use clarithromycin (vs no treatment) for the treatment of idiopathic hypersomnia in adults. (CONDITIONAL)}}</ref><ref name="AASM GAG">{{cite web |title=Treatment of Central Disorders of Hypersomnolence: An American Academy of Sleep Medicine Clinical Practice Guideline - Guidelines at a Glance |url=https://aasm.org/wp-content/uploads/2022/03/Treatment_Central_Disorders_Hypersomnolence_Guideline_at_a_Glance.pdf |publisher=American Academy of Sleep Medicine |access-date=25 February 2024 |archive-url=https://web.archive.org/web/20240225104203/https://aasm.org/wp-content/uploads/2022/03/Treatment_Central_Disorders_Hypersomnolence_Guideline_at_a_Glance.pdf |archive-date=25 February 2024 |date=2021 |url-status=live}}</ref>